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ABSTRACT
Botulinum toxin (BoNT) injections are an effective
treatment for cervical dystonia. Approximately
20% of patients eventually stop BoNT treatment,
mostly because of treatment failure. These
recommendations review the different
therapeutic interventions for optimising the
treatment in secondary poor responder patients.
Immunoresistance has become less common over
the years, but the diagnosis has to be addressed
with a frontalis test or an Extensor Digitorum
Brevis test. In case of immunoresistance to BoNT-
A, we discuss the place the different therapeutic
options (BoNT-A holidays, BoNT-B injections,
alternative BoNT-A injections, deep brain
stimulation). When poor responders are not
immunoresistant, they benefit from reviewing (1)
injections technique with electromyography or
ultrasound guidance, (2) muscles selection and
(3) dose of BoNT. In addition, in both scenarios,
a holistic approach including drug treatment,
retraining and psychological support is valuable
in the management of these complex and severe
cervical dystonia.
Cervical dystonia impairs quality of life
and leads to social and occupational dis-
ability: botulinum toxin injections are an
effective treatment.1 About 20% of
patients with cervical dystonia eventually
stop botulinum toxin treatment, mostly
after treatment failure.2 Spontaneous
remission, improvement after long-term
treatment or difficulty accessing the treat-
ment (eg, living in remote areas) can also
lead to stopping the treatment.
These recommendations review the
therapeutic interventions to optimise the
treatment of patients with a poor
response. We provide references that give
the evidence base to guide treatment; the
non-referenced advice should be taken as
the authors’ opinion, based on experi-
ence. The British Neurotoxin Network
members, at the annual meeting in
Oxford in September 2015, have
endorsed these guidelines.
DEFINITIONS AND TERMINOLOGY
▸ Poor responders (treatment failures) are
those who, subjectively or from the
doctor’s observation, do not achieve
adequate symptom relief (primary or sec-
ondary non-responders) or who develop
intolerable adverse effects from treatment
(dysphagia, neck extensors weakness).3
▸ Primary non-responders are those in whom
botulinum toxin treatment has never helped.
▸ Secondary non-responders are those who
fail to respond following previously suc-
cessful treatment to botulinum toxin. A
widely accepted definition of secondary
non-response is “an unsatisfactory thera-
peutic response to two successive injection
cycles, where the patient has previously
received a minimum of two successful
treatment cycles”.4
▸ We use UK brand names of botulinum toxin
preparations to facilitate the use of these
guidelines to UK injectors. Table 1 shows the
different preparations of botulinum toxin
type A (botulinum toxin-A) and botulinum
toxin type B (botulinum toxin-B) with their
brand names and their US generic names, as
requested by the FDA to emphasise the dif-
ference between these preparations.5
CHALLENGES WHEN TREATING
CERVICAL DYSTONIAWITH
BOTULINUM TOXIN
Botulinum toxin treatment has to be cus-
tomised to each individual patient. The
injector’s skill comprises a combination
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of postural analysis, identification of offending muscle
groups, optimisation of dosage, dilution ratios, inter-
val between injections, injection technique and, when
necessary, targeting the muscles guided by electromyo-
graphy (EMG) or ultrasound. The optimal treatment
will relieve the patient’s disability with minimal or no
adverse effects.
REASONS FOR TREATMENT FAILURES
There have been several studies looking at large
cohorts of patients with cervical dystonia and the
reasons for treatment failures.4 6–9 Most poor
responses relate to suboptimal treatment and a minor-
ity to immunoresistance from developing neutralising
antibodies. Secondary non-response (to two consecu-
tive injections cycles) may also relate to underlying
disease progression.10
Adverse effects can limit optimal treatment, in par-
ticular, dysphagia, in patients receiving bilateral injec-
tions of sternocleidomastoid or longus colli, when
there are pre-existing swallowing difficulties11 or in
craniocervical dystonia when injections target both
neck and tongue muscles.
Some patients perceive a poor response through
unrealistic expectations, depressed mood or when
they compare their current response to the initial
response, which may have had the most noticeable
benefit.
IMMUNORESISTANCE
Prevalence of immunoresistance in non-responders
Recent studies show relatively low rates of neutralising
antibodies with using botulinum toxin-A,12 and that
these antibodies are not closely associated with treat-
ment failure. Rates of treatment failure associated
with neutralising antibodies with Dysport range from
0%10 to 2.5%,4 with Xeomin range from 0%13 to 1%
in patients who had previously received other botu-
linum toxin-A products,14 and with Botox from 0%13
to 1.2%.16
Earlier reports of a higher prevalence neutralising
antibodies (17–23%) may be because the original
toxin formulation had a higher protein concentra-
tion.15 17
Botulinum toxin-B was approved to treat cervical
dystonia in 2001 in the UK and may be an alternative
for patients resistant to botulinum toxin-A. Botulinum
toxin-B is effective and safe in the long-term treat-
ment of cervical dystonia,18 but its higher immuno-
genicity—in particular, in patients already resistant to
botulinum toxin-A—may limit its use as a therapeutic
alternative.19–20
Neutralising antibody titres to botulinum toxin-A
decline after stopping botulinum toxin therapy in
resistant patients.21 The rate of decline varies consid-
erably between individuals, and it can take up to
4 years after stopping treatment before the antibody
titres become undetectable.21 Antibody titres also
decline in resistant patients when treated with
Xeomin.21 However, in one report a patient pre-
treated with Dysport developed a secondary antibody-
induced treatment failure under therapy with
Xeomin.22 Therefore, we await confirmation of the
efficacy of Xeomin in resistant patients.
Early diagnosis of immunoresistance
Botulinum toxin-A resistance may occur very early in
the course of treatment, usually within 2–3 years after
starting treatment; the response usually fails gradually,
starting with reduced duration of clinical effect, fol-
lowed by significantly reduced maximal effect.7
Patients with cervical dystonia should therefore be
carefully monitored with scoring of the treatment
effect in order to detect immunoresistance early,
thereby avoiding complete therapy failure with high
titres of neutralising antibodies.23 Objective tests
include unilateral injection of the frontalis muscle or
injection of the extensor digitorum brevis of the foot
with botulinum toxin-A. The frontalis test is the most
frequently used method.24 Any evidence of paralysis
(frontalis or extensor digitorum brevis test) excludes
immunoresistance as the cause of treatment failure.
Frontalis test
Two injections of 30 units Dysport or 10 units
Botox25 or Xeomin are given to the forehead about
3 cm above the lateral and medial canthus of one
eye (figure 1). The response is assessed 2–4 weeks
later by asking the patient to raise their eyebrows: an
asymmetric response indicates that botulinum toxin
has been effective.25 To avoid equivocal results (espe-
cially in cases of partial resistance), it is valuable to
compare photographs or videos before and after injec-
tion. If the frontalis test is equivocal, the clinician can
use a higher dose of botulinum toxin-A or perform
the extensor digitorum brevis test to give quantified
data.
Extensor digitorum brevis test using EMG (electrical stimulation)
For the extensor digitorum brevis test, 100 units
Dysport or 20 units Botox are injected into the
Table 1 Different preparations of botulinum toxin
US generic name
Brand
name Manufacturer
Packaging
Units/phial
OnabotulinumtoxinA Botox Allergan 50, 100, 200
AbobotulinumtoxinA Dysport Ipsen 300, 500
IncobotulinumtoxinA Xeomin Merz
Pharmaceuticals
50, 100
RimabotulinumtoxinB NeuroBloc Eisai Ltd 2500, 5000, or
10 000
These four preparations are available and licensed in the UK for the
treatment of cervical dystonia. The units between these different
preparations are not equivalent, and the clinician must be vigilant when
switching from one preparation to another. As an indication, 1 unit
Botox=1 unit Xeomin=3 units Dysport=50 units Neurobloc for cervical
dystonia.
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muscle on one side. EMG measures the compound
muscle action potential (CMAP) of the extensor digi-
torum brevis using electrical stimulation of the pero-
neal nerve at baseline and 2 weeks after botulinum
toxin-A injection.26 If the toxin is biologically active,
the CMAP should fall by >50% of the baseline
values, usually with evidence of atrophy and weak-
ness. A fall in CMAP of <20% suggests the presence
of neutralising antibodies; a 20–50% decrease is
equivocal.
MEDICAL AND SURGICAL TREATMENT OF
CERVICAL DYSTONIA
There are only a few studies on drug treatment in dys-
tonia.27 28 A comparison28 of botulinum toxin-A
(mean dose 292 units Dysport) versus trihexyphenidyl
(mean dose 16.25 mg) in cervical dystonia favoured
botulinum toxin-A. Recent experimental evidence sug-
gests that anticholinergic drugs can help dystonia29
but patient’s increased risk of dementia from long-
term anticholinergic drugs is a concern.30
Surgical treatment of cervical dystonia has evolved
from peripheral denervation to pallidal deep brain
stimulation (GPi-DBS).31 A recent comparative study
between the two procedures favoured GPi-DBS,
which gave greater benefit but with potentially more
severe complications.32 Bradykinesia, leg stiffness and
freezing of gait can develop with high-frequency
stimulation GPi-DBS in cervical dystonia.33
RECOMMENDATIONS FOR MANAGING PRIMARY
POOR RESPONDERS AND SECONDARY
NON-RESPONDERS
A European survey of management of secondary non-
response to botulinum toxin-A in cervical dystonia
found that the physicians’ most common practice was
to optimise physiotherapy (98%), to increase the dose
of botulinum toxin-A (89%), to target new muscles
with the treatment (91%) and to use EMG (86%).
Also, 64% of physicians considered switching to botu-
linum toxin-B and 73% considered switching to DBS;
18% considered peripheral denervation.24
Figure 1 (A) Frontalis test: unilateral injection of the frontalis muscle with botulinum toxin (BoNT). (B) Patient non-resistant to BoNT:
paralysis of the frontalis muscle and incapacity to raise the eyebrow on the side of the injection. (C) Patient resistant to BoNT:
absence of paralysis of the frontalis muscle on the side of the injection and symmetrical elevation of eyebrows.
Figure 2 Algorithm for the management of patients with cervical dystonia who have a poor response to botulinum toxin treatment.
BoNT, botulinum toxin; CD, cervical dystonia; DBS, deep brain stimulation; EMG, electromyography.
REVIEW
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There are no published guidelines for managing
patients with cervical dystonia who are poor respon-
ders. From the above evidence and from our UK clin-
ical experience, we propose an algorithm in figure 2
to support the UK injectors.
Document the poor clinical response
▸ Assess the patient before injection and preferably 1
month after the injections using either a rating scale or
goniometric measurement of head posture and/or video
clips of the patient sitting, standing, walking; sitting eyes
opened and closed; and performing active movement of
head.
▸ Document wasting of injected muscles, in particular, the
sternocleidomastoid.
▸ Ask patients specifically about dysphagia (fluid or solids)
before and after injections. Adverse effects may limit
dose but are clear evidence of ongoing sensitivity to
botulinum toxin.
▸ If botulinum toxin-A appears effective (muscle atrophy,
side effects), revise the injection protocol (muscle selec-
tion, doses, injection technique).
Review the muscle selection
▸ Patients often have a mixed pattern of cervical dystonia
(figure 3) (typically a combination of extension, rotation
and tilt to different degrees) rather than pure rotation,
tilt, flexion or extension; this makes a dystonic move-
ment very different from a normal purposeful head/neck
movement (tables 2–4). More rarely there is lateral and
sagittal shift of the head and neck. Often the scapular
muscles are also involved in the abnormal posture of
head and neck.
▸ The patient may adopt a compensatory posture in oppos-
ition to the dystonic spasm, which can be misleading for
the clinician. Therefore, analysing the dystonic posture
can be difficult; in addition, there can be tremor and
myoclonus superimposed on the dystonic spasms.
▸ Be sure to observe the patient at their worst. Abnormal
postures can be variable and task-specific (eg, walking,
running, drinking, writing, answering the telephone).
Video clips of daily activities can help.
▸ Examine the shoulder muscles, looking for elevation of
one shoulder, comparing the position of the scapulae
and assessing hypertrophy of the scapular portion of the
levator scapulae. Be aware (figure 4) of the synergy
between contralateral sternocleidomastoid and contralat-
eral trapezius, and between ipsilateral levator scapulae
and ipsilateral splenius for rotation (table 3). Shoulder
elevation on the side of rotation therefore suggests dys-
tonic levator scapulae, and shoulder elevation on the
opposite side of rotation suggests dystonic trapezius
(figure 4).
Figure 3 Mixed dystonic head posture: rotation of the head to
the right, extension and tilt to the left with elevation of right
shoulder. The muscles involved are left sternocleidomastoid,
right splenius and right levator scapulae.
Table 2 Posterior muscle layers of the neck
Four layers
Superficial layer;
oblique running posterior to anterior
Trapezius
Layer of muscles, oblique anterior to
posterior
Splenius capitis and cervicis
Levator scapulae
Layer of muscles with vertical orientation Semispinalis capitis
Longissimus capitis and
cervicis
Deep layer Suboccipital muscles
Multifidi muscles
Table 3 The main group of muscles involved in dystonic posture
Action Muscles groups
Torticollis Contralateral sternocleidomastoid
Contralateral trapezius
Ipsilateral splenius capitis
Ipsilateral levator scapulae
Laterocollis Ipsilateral sternocleidomastoid
Ipsilateral splenius capitis
Ipsilateral levator scapulae
Ipsilateral trapezius
Retrocollis Bilateral splenius
Bilateral semispinalis
Antecollis Bilateral sternocleidomastoid
Bilateral longus colli
Bilateral scalenus
This table guides the clinical examination to certain muscles.
Table 4 Muscles involved in lateral shift of the head, also
known as ‘Bali dancer’s posture’
Tilt of head to one
side
Tilt of the neck to the
contralateral side
Head attachment
muscles
Ipsilateral
sternocleidomastoid
Ipsilateral splenius
capitis
Ipsilateral trapezius
Ipsilateral semispinalis
capitis
Cervical spine
attachment muscles
Contralateral levator
scapulae
Contralateral scalenus
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▸ In laterocollis, after a few injections the patient may
develop a horizontal translation of the head with the
shift of the neck towards one side and the head towards
the opposite side (figure 5, table 4). This lateral shift of
the head is very similar to the so-called ‘head slide’
movement seen in Balinese dance.
▸ In cases of posterior sagittal shift (double-chin posture;
figure 5), we recommend injecting the longus colli and
the supra-hyoid muscles. In cases of anterior sagittal
shift (goose-neck posture; figure 5), we recommend
injecting both bilateral sternocleidomastoid and bilateral
splenius capiti.34
▸ In antecollis (figure 6), it is often not sufficient to inject
both sternocleidomastoids. In cases of double-chin
posture (table 5), clinicians should consider additional
injection of longus colli and the supra-hyoid muscles. Be
aware of the risk of dysphagia with these injections.
▸ In cases of severe retrocollis (figure 6), it is difficult, in
practice, to distinguish the extension of the cervical
spine (hyperlordosis) from the extension of the head on
cervical spine. In that case, it is more important to
choose a high dose of botulinum toxin (see section
‘Review dosage’) and an appropriate needle (see section
‘Review injection technique’) rather than to try to distin-
guish each muscle of the posterior cervical region during
the injections as all the posterior cervical muscles can be
involved in the extension (table 2).
▸ The suboccipital muscles may be involved in some
abnormal postures of the head such as rotation, exten-
sion or tilt of head on the cervical spine. However,
injecting these muscles may carry risk due to the proxim-
ity of the vertebral artery.
Review dosage
▸ The dose can be increased according to the clinical effect
of previous injections.
▸ The dose injected into sternocleidomastoid is limited by
the risk of dysphagia; the recommended dose is 50–
100 units of Botox/Xeomin in two sites (SPC data) and
150 units of Dysport. In our experience, the splenius
requires a much larger dose than the
sternocleidomastoid.
▸ The total dose can be increased up to 1000 units
Dysport and 300 units Botox/Xeomin (SPC data).
Patients with retrocollis often need large doses.
Review injection technique
▸ The needle used to inject the posterior cervical muscles
from the second and third muscles layers (table 2) needs
to be long enough to reach these muscles; we recom-
mend using long blue needles (23 g/31.5 mm) or grey
needles (27 g/40 mm).
▸ Consider EMG-guided or ultrasound-guided injections if
there is suspected deep muscle involvement or, in patients
with a thick neck, to help target the dystonic muscles.
Have a holistic therapeutic approach
▸ Review the drug treatment and consider a retraining pro-
gramme (physiotherapy, mindfulness, mental imagery),
Figure 4 (A) Clinical selection of scapular muscles depending on the side of the elevation of the shoulder in a patient with dystonic
head rotation. (B) Identical muscle fibre orientation explains the synergy of action in the rotation of the head between
sternocleidomastoid and trapezius and between splenius and levator scapulae.
Table 5 Muscles involved in sagittal shift of the head
Anterior sagittal
shift
‘Goose-neck posture’
Posterior sagittal
shift
‘Double-chin posture’
Head attachment
muscles
Bilateral
sternocleidomastoid
Bilateral splenius capitis
Bilateral longus colli
Bilateral
sternocleidomastoid
Supra-hyoid muscles
The anterior sagittal shift of the head, also called ‘goose-neck posture’,
can be the first step of the swing of the head backward with extension of
head on cervical spine and cervical spine on thoracic spine. The posterior
sagittal shift of the head also called ‘double-chin posture’, can be the first
step of the swing of the head forward with flexion of head on cervical
spine and cervical spine on thoracic spine.
REVIEW
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taking into account stressful events, which can make the
dystonia transiently worst.
▸ Anticholinergic drugs, in particular, trihexyphenidyl,
may help the spasms and are usually well tolerated if
introduced very gradually over few months. They are
used up to a typical dose of 6 mg/day according to
response and side effect profile, although some experi-
enced clinicians may choose use higher doses.
Anticholinergic drugs particularly help poor responding
patients, and their prescription should be reviewed
annually.
▸ Benzodiazepines, in particular, clonazepam, may help
those with additional tremor or myoclonus. These
should also be introduced very gradually, aiming for a
maximum dose of 1.5 mg/day. The patient should be
warned about habituation and tolerance.
Consider immunoresistance
If there is evidence of loss of botulinum toxin-A effi-
cacy (poor clinical response, absence of muscle
wasting and absence of side effects), undertake a fron-
talis test or an extensor digitorum brevis test to diag-
nose immunoresistance; this should be done early to
avoid further increase of antibodies titres.
For patients with immunoresistance to botulinum
toxin A, there are two initial options:
1. Use NeuroBloc (botulinum toxin-B) injections.
2. Suspend injections for 12–18 months, reviewing the
patient regularly. If they have impaired quality of life,
start a new cycle of injections using an alternative botu-
linum toxin-A.
If there is no clinical response or if patients develop
further immunoresistance to botulinum toxin-B, con-
sider DBS.
Referral to expert centre for second opinion
We advise referral to an expert centre in the following
circumstances:
▸ if the severity of dystonia is not controlled despite
reviewing injection protocol;
▸ when there is a very complex dystonic posture, such as
antecollis, horizontal or sagittal shift of the head requir-
ing injection of deep muscles such as longus colli, sca-
lenus or the suboccipital muscles;
▸ when large doses of toxin are required (up to 400 units
Botox-or Xeomin and 1500 units of Dysport), for severe
dystonic spasms, involving more than three large muscles
(splenius, semispinalis, levator scapulae, trapezius);
▸ when DBS is indicated (patient has a poor quality of life
despite optimal treatment or in cases of immunoresistance).
Figure 5 (A) Posterior shift of the head or double chin. (B) Anterior shift of the head or goose neck. (C) Lateral shift of the head:
the contralateral shift of the neck to the right allows the patient to have a horizontal gaze despite a tilt of his head to the left.
Figure 6 (A) Antecollis posture with flexion of head and neck. (B) Retrocollis posture with extension of head and neck.
REVIEW
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CONCLUSIONS
It is important to be alert to a patient’s complaints of
poor response to botulinum toxin treatment despite
the difficulties of working in often overloaded and
routine clinics with short timeslots for treatment.
In such cases, it is important to be proactive
without delay:
▸ Review injection technique (with EMG guidance), dose
and selection of muscles to improve the efficacy of the
injections.
▸ Look for immunoresistance by frontalis or extensor digi-
torum brevis test.
▸ Refer to an expert centre for challenging and complex cases
for advice and to discuss surgical options (such as DBS).
Secondary non-response is not necessarily a failure
but is a therapeutic challenge for which there may be
specific answers.
Key points
▸ Immunological resistance to botulinum toxin type
A is becoming rare, but early diagnosis is important.
▸ Most patients with cervical dystonia who are non-
responders require review of the clinical analysis of
the dystonic posture.
▸ Do not forget to examine the shoulders as levator
scapulae and trapezius are powerful muscles!
▸ Severe cervical dystonia requires a high dose range of
botulinum toxin type A.
▸ Think beyond botulinum toxin type A injections: a
holistic approach with physical retraining is an
important part of the treatment.
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